Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Emoxypine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.44 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.37 |
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.37 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.36 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emoxypine SCHEMBL31074958 | 1.00 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL11089142 | 1.00 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL195347 | 0.98 | KDM4E (0.72) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL29362452 | 0.98 | KDM4E (0.72) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL11089145 | 0.96 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL1373711 | 0.93 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL21061700 | 0.93 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL26983696 | 0.93 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL1010987 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL30182715 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1878431-B1 | MEDICINAL AGENT FOR PREVENTING PROGRESSION OF APOPTOTIC AND JUGULATING NECROTIC CHANGES IN THE ORGANISM TISSUES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU N PROIZV KOMPANIA FARMASOFT (RU) | 2011-04-06 | — | — | EP | claimed |
| EP-1878431-A1 | MEDICINAL AGENT FOR PREVENTING PROGRESSION OF APOPTOTIC AND JUGULATING NECROTIC CHANGES IN THE ORGANISM TISSUES | Sukoyan, Galina Victorovna (RU) | 2008-01-16 | — | — | EP | claimed |
| US-4486440-A | Retinoprotector for treating intraocular hemorrhage, myopic, chorioretinal dystrophies, congenital retinal dystrophies, retinal burns and prevention of injury in lasercoagulation | INSTITUT KHIMICHESKOI FIZIKI (SU) | 1984-12-04 | — | — | US | claimed |
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2025-04-10 | — | — | US | disclosed |
| EP-3704098-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-112154142-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230144871-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210113532-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778575-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112154142-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2020-12-29 | — | — | CN | disclosed |
| US-10864196-B2 | Modulators of the integrated stress pathway | CALICO LIFE SCIENCES, LLC (US) | 2020-12-15 | — | — | US | disclosed |
| US-20100310646-A1 | SELECTIVE EXOSITE INHIBITION OF PAPP-A ACTIVITY AGAINST IGFBP-4 | AARHUS UNIVERSITET (DK) | 2010-12-09 | — | — | US | disclosed |
| WO-2010059706-A2 | TRANSLATION FACTORS AS ANTI-AGING DRUG TARGETS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20080234310-A1 | Methods and Compositions for Slowing Aging | MEDIVATION, INC. | 2008-09-25 | — | — | US | disclosed |
| EP-1692131-A4 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION INC (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1878431-A1 | MEDICINAL AGENT FOR PREVENTING PROGRESSION OF APOPTOTIC AND JUGULATING NECROTIC CHANGES IN THE ORGANISM TISSUES | Sukoyan, Galina Victorovna (RU) | 2008-01-16 | — | — | EP | disclosed |
| US-20070179174-A1 | Methods and compositions for slowing aging | MEDIVATION, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1692131-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005055951-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-4486440-A | Retinoprotector for treating intraocular hemorrhage, myopic, chorioretinal dystrophies, congenital retinal dystrophies, retinal burns and prevention of injury in lasercoagulation | INSTITUT KHIMICHESKOI FIZIKI (SU) | 1984-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179174-A1 | Methods and compositions for slowing aging | PRDX5, HMOX1, SHMT2 | OPRK1 3469/4885HDAC6 855/4885CCR5 3217/4885 |
| US-20230144871-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | OPRK1 680/4885HDAC6 437/4885CCR5 4223/4885 |
| US-20210113532-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | OPRK1 680/4885HDAC6 437/4885CCR5 4223/4885 |
| US-10864196-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | OPRK1 680/4885HDAC6 437/4885CCR5 4223/4885 |
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | OPRK1 680/4885HDAC6 437/4885CCR5 4223/4885 |
| US-20080234310-A1 | Methods and Compositions for Slowing Aging | PRDX5, HMOX1, SHMT2 | OPRK1 3469/4885HDAC6 855/4885CCR5 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.